**REDUCTION IN INFLAMMATORY AND NONINFLAMMATORY ACNE**

TAZORAC® (tazarotene) CREAM 0.1% vs vehicle

### Phase 3 Pivotal Trial Results at Week 12—Cream Study 1

<table>
<thead>
<tr>
<th>Percentage Reduction</th>
<th>TAZORAC Cream 0.1% (n = 206)</th>
<th>Vehicle cream (n = 205)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Noninflammatory</td>
<td>46%</td>
<td>27%</td>
</tr>
<tr>
<td>Inflammatory</td>
<td>41%</td>
<td>27%</td>
</tr>
<tr>
<td>Total</td>
<td>44%</td>
<td>24%</td>
</tr>
<tr>
<td>Percentage of Subjects with No Acne</td>
<td>55%</td>
<td>36%</td>
</tr>
</tbody>
</table>

### Phase 3 Pivotal Trial Results at Week 12—Cream Study 2

<table>
<thead>
<tr>
<th>Percentage Reduction</th>
<th>TAZORAC Cream 0.1% (n = 218)</th>
<th>Vehicle cream (n = 218)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Noninflammatory</td>
<td>41%</td>
<td>21%</td>
</tr>
<tr>
<td>Inflammatory</td>
<td>44%</td>
<td>25%</td>
</tr>
<tr>
<td>Total</td>
<td>42%</td>
<td>21%</td>
</tr>
<tr>
<td>Percentage of Subjects with No Acne</td>
<td>53%</td>
<td>36%</td>
</tr>
</tbody>
</table>

### GAAS Results

**Percentage of Subjects With a Global Assessment Score of at Least 3 (≥ 50% Global Improvement at 12 Weeks—Studies 1 and 2)**

- TAZORAC Cream 0.1% (n = 424)
- Vehicle cream (n = 423)

- 54% vs 31%

---

**Adverse events**

The most frequent adverse reactions reported during clinical trials with TAZORAC Cream 0.1% in the treatment of acne, occurring in 10% to 30% of patients, in descending order, included desquamation, dry skin, erythema, and burning sensation.

Events occurring in 1% to 5% of patients included pruritus, irritation, face pain, and stinging.
Results of 2 large, vehicle-controlled studies (of patients aged 12 years or older) comparing TAZORAC Gel 0.1% and vehicle gel.

### Phase 3 Pivotal Trial Results at Week 12—Gel Study 1

- **Median Percentage Reduction in Noninflammatory Lesions**
  - TAZORAC Gel 0.1%: 55%
  - Vehicle Gel: 35%

- **Median Percentage Reduction in Inflammatory Lesions**
  - TAZORAC Gel 0.1%: 42%
  - Vehicle Gel: 30%

- **Median Percentage Reduction in Total Lesions**
  - TAZORAC Gel 0.1%: 52%
  - Vehicle Gel: 33%

### Phase 3 Pivotal Trial Results at Week 12—Gel Study 2

- **Median Percentage Reduction in Noninflammatory Lesions**
  - TAZORAC Gel 0.1%: 43%
  - Vehicle Gel: 27%

- **Median Percentage Reduction in Inflammatory Lesions**
  - TAZORAC Gel 0.1%: 47%
  - Vehicle Gel: 28%

- **Median Percentage Reduction in Total Lesions**
  - TAZORAC Gel 0.1%: 45%
  - Vehicle Gel: 27%

### GAAS Results

- **Percentage of Subjects with a Treatment Success Rate of ≥ 50% Improvement at 12 Weeks—Studies 1 and 2**
  - TAZORAC Gel 0.1%: 68%
  - Vehicle Gel: 40%

Results of 2 large, vehicle-controlled studies (of patients aged 12 years or older) comparing TAZORAC Gel 0.1% and vehicle gel.

### Adverse events

The most frequent adverse reactions reported during clinical trials with TAZORAC Gel 0.1% in the treatment of acne, occurring in 10% to 30% of patients, in descending order, included desquamation, burning/stinging, dry skin, erythema, and pruritus.

Events occurring in 1% to 10% of patients included irritation, skin pain, fissuring, localized edema, and skin discoloration.

### References

1. Tazorac Cream and Gel 0.1% and 0.05% Prescribing Information; August 2019.

TAZORAC® is a registered trademark of Almirall, LLC.